Home Featured Page 160

Featured

Latest

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

It’s Time to Push Back: Meta’s War on Psychedelic Voices

MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results...

Numinus Wellness Inc. Reports Q2 2022 Results

PT313 – Christine Calvert, LCDC – Holotropic Breathwork, Ethics, and Dying...

Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial...

Filament Health and Psyence Enter into Exclusive Licensing Agreement for Natural...

Psychedelic Bulletin: Psychedelics X Big Pharma; $23m Round for At-Home Ketamine...

MYND Life Sciences Announces $3.5 Million Share Offering

Psychedelic Research Bulletin: March 2022

PT312 – Deborah Snyder – Ecology, Synergy, and the Biosphere

COMPASS Pathways partners with One Mind to fund Rising Star Awards...

1...159160161...291 Page 160 of 291

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

It’s Time to Push Back: Meta’s War on Psychedelic Voices

MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results...

Numinus Wellness Inc. Reports Q2 2022 Results

PT313 – Christine Calvert, LCDC – Holotropic Breathwork, Ethics, and Dying...

Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial...

Filament Health and Psyence Enter into Exclusive Licensing Agreement for Natural...

Psychedelic Bulletin: Psychedelics X Big Pharma; $23m Round for At-Home Ketamine...

MYND Life Sciences Announces $3.5 Million Share Offering

Psychedelic Research Bulletin: March 2022

PT312 – Deborah Snyder – Ecology, Synergy, and the Biosphere

COMPASS Pathways partners with One Mind to fund Rising Star Awards...

EDITOR PICKS

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY